Sino Biopharmaceutical 

Sino Biopharmaceutical Limited, an investment holding company, researches and develops, produces, and sells Chinese and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in three segments: Chemical Medicines and Biopharmaceutical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianding tablets, Tianqingganping enteric capsules, Mingzheng capsules, and Ganze entecavir capsules; cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Kaina tablets, and Tianqingning injections; and oncology medicines consisting of Saiweijian, Tianqingyitai, Qingweike, and Zhiruo injections, as well as Focus V and Genike capsules, and Shoufu and Yinishu tablets. The company's principal products also comprise Analgesic medicines, such as Kaifen injections and Debaian Cataplasms; Orthopedic medicines, which include Gaisanchun capsules and Jiuli tablets; digestive system medicines, such as Aisuping injections and Getai tablets; anti-infectious medicines consisting of Tiance injections and Tianjie tablets; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections. In addition, it is involved in the development of medicines for tumor, liver, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management and healthy information services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.